RMC-4745

RMC-4745 is a selective dual-site inhibitor of mTORC1, demonstrating a 35-fold selectivity over mTORC2. It inhibits the proliferation of MCF-7 cells and induces apoptosis by upregulating Caspase-3/7 activity. Notably, RMC-4745 does not trigger HER3 upregulation, which typically results from mTORC2 inhibition. This compound is useful for breast cancer research.